Research programme: obesity therapeutics - Theracos
Alternative Names: THR-4218Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Theracos
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 09 Nov 2009 Preclinical trials in Obesity in USA (PO)